• 1
    Stevens RF, Hann IM, Wheatley K, et al. Marked improvements in outcome with chemotherapy alone in pediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. Br J Haematol. 1998; 101: 130140.
  • 2
    Creutzig U, Ritter J, Zimmermann M, et al., for the Acute Myeloid Leukemia – Berlin-Frankfurt-Munster Study Group. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of study Acute Myeloid Leukemia Berlin-Frankfurt-Munster 93. J Clin Oncol. 2001; 19: 27052713.
  • 3
    Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children's Cancer Group. Blood. 2001; 97: 5662.
  • 4
    O'Brien TA, Russell SJ, Vowels MR, et al. Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children's Cancer Study Group. Blood. 2002; 100: 27082716.
  • 5
    Lie SO, Abrahamsson J, Clausen N, et al. Treatment stratification based on initial in vivo response in acute myeloid leukemia in children without Down's syndrome: results of NOPHO-AML trials. Br J Haematol. 2003; 122: 217225.
  • 6
    RiesLAG, EisnerMP, KosaryCL, et al. (eds.). SEER Cancer Statistics Review, 1975-2001, National Cancer Institute. Bethesda, MD. Available from URL: [accessed December 14, 2005].
  • 7
    Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999; 341: 10511062.
  • 8
    Webb DK, Harrison G, Stevens RF, et al. Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood. 2001; 98: 17141720.
  • 9
    Horibe K, Tsukimoto I, Ohno R. Clinicopathologic characteristics of leukemia in Japanese children and young adults. Leukemia. 2001; 15: 12561261.
  • 10
    Rubnitz JE, Lensing S, Zhou Y, et al. Death during induction therapy and first remission of acute leukemia in childhood, the St. Jude experience. Cancer. 2004; 101: 16771684.
  • 11
    Godder K, Eapen M, Laver JH, et al. Autologous hematopoietic stem-cell transplantation for children with acute myeloid leukemia in first or second complete remission: a prognostic factor analysis. J Clin Oncol. 2004; 22: 37983804.
  • 12
    Neudrof S, Sanders J, Kobrinsky N, et al. Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. Blood. 2004; 103: 36553661.
  • 13
    Kalwinsky D, Mirro J Jr., Schell M, et al. Early intensification of chemotherapy for childhood acute nonlymphoblastic leukemia: Improved remission induction with a five-drug regimen including etoposide. J Clin Oncol. 1988; 6: 11341143.
  • 14
    Arnaout MK, Radomski KM, Srivastava DK. Treatment of childhood acute myelogenous leukemia with an intensive regimen (AML-87) that individualizes etoposide and cytarabine dosages: short- and long-term effects. Leukemia. 2000; 14: 17361742.
  • 15
    Krance RA, Hurwitz CA, Head DR, et al. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J Clin Oncol. 2001; 19: 28042811.
  • 16
    Crews KR, Ghandi V, Srivastava DK, et al. An interim comparison of a continuous infusion versus a short daily infusion of cytarabine given with cladribine for pediatric acute myeloid leukemia. J Clin Oncol. 2002; 20: 42174224.
  • 17
    Estey E, Thall P, Kantarjian H, et al. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony stimulating factor (GM-CSF) before and during continuous-infusion high dose ara-C + daunomycin: comparison to patients treated without GM-CSF. Blood. 1992; 79: 22462255.
  • 18
    Estey EH. Treatment of acute myelogenous leukemia. Oncology. 2002; 16: 343346.
  • 19
    Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood. 1996; 87: 49794989.
  • 20
    Grimwade D, Walker H, Oliver F, et al. on behalf of the Medical Research Council Adult and Children's Leukaemia Working Parties. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998; 92: 23222333.
  • 21
    Ravindranath Y, Abella E, Krisher JP, et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood. 1992; 80: 22102214.
  • 22
    Rubnitz JE, Raimondi SC, Tong X, et al. Favorable impact of the t(9;11) in childhood acute myeloid leukemia. J Clin Oncol. 2002; 20: 23022309.
  • 23
    Raimondi SC, Chang MN, Ravindranath Y, et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood. 1999; 94: 37073716.
  • 24
    Agresti A. Categorical Data Analysis. New York: John Wiley & Sons, 1990: 4754, 62–65.
  • 25
    Hollander M, Wolfe DA. Non Parametric Statistical Methods. New York: John Wiley & Sons, 1999: 106125.
  • 26
    Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observations of each patient. II. Analysis and examples. Br J Cancer. 1977; 35: 139.
  • 27
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22: 719748.
  • 28
    Cox DR. Regression models and life tables. J R Stat Soc [Ser B]. 1972; 20: 187220.
  • 29
    Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons, 1980.
  • 30
    Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16: 11411154.
  • 31
    Sekeres MA, Stone RM. The challenge of acute myeloid leukemia in older patients. Curr Opin Oncol. 2002; 14: 2430.
  • 32
    Stirewalt DL, Kopeky KJ, Meshinchi S, et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood. 2001; 97: 35893595.
  • 33
    Lichtman MA, Rowe JM. The relationship of patient age to the pathobiology of the clonal myeloid diseases. Semin Oncol. 2004; 31: 185197.
  • 34
    Estey EH. How I treat older patients with AML. Blood. 2000; 96: 16701673.
  • 35
    Meshinshi S, Alonzo TA, Gerbing RB, et al. Clinical significance of FLT3 internal tandem duplication in pediatric AML, a CCG 2961 study [Abstract]. Blood. 2000; 102(Suppl): 98a.
  • 36
    Meshinchi S, Woods WG, Stirewalt DL, et al. Prevalence and prognostic significance of FLT3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 2001; 97: 8994.
  • 37
    Pui C-H, Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998; 339: 605615.
  • 38
    Stock W, Sather H, Dodge RK, et al. Outcome of adolescents and young adults with ALL: a comparison of Children's Cancer Group (CCG) and Cancer and Leukemia Group B (CALGB) regimens [Abstract]. Blood. 2000; 96: 467a.
  • 39
    Boissel N, Auclerc M-F, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003; 21: 774780.
  • 40
    de Bont JM, van der Holt B, Dekker AW, et al. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia. 2004; 18: 20322035.
  • 41
    Schiffer CA. Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both? J Clin Oncol. 2003; 21: 760761.
  • 42
    Tebbi CK, Cummings KM, Zevon MA, et al. Compliance of pediatric and adolescent cancer patients. Cancer. 1986; 58: 11791184.
  • 43
    Peeters M, Oren G, Jakubovicz D, et al. Physicians compliance and relapse rates of acute lymphoblastic leukemia in children. Clin Pharmacol Ther. 1988; 43: 228232.
  • 44
    Davies HA, Lilleyman JS. Compliance with oral chemotherapy in childhood lymphoblastic leukemia. Cancer Treat Rev. 1995; 21: 93103.
  • 45
    Sekeres MA, Peterson B, Dodge RK, et al. Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood. 2004: 40364042.
  • 46
    Davies SM, Alonzo TA, Lange B, et al. Reduced survival in black children with acute myeloid leukemia: a Children's Cancer Study Group [Abstract]. Blood. 2002: 35a.